Quantum SI

Quantum SI

QSIPre-clinical
Founded 2013quantum-si.com

Founded in 2013 by Jonathan Rothberg, Quantum-Si is on a mission to power the post-genomic era by democratizing single-molecule protein analysis. Its flagship Platinum Pro instrument and associated kits provide a streamlined workflow for applications ranging from protein identification and variant detection to antibody characterization and ultrasensitive protein detection. As a public company, Quantum-Si is positioned to transform proteomics research and drug development by offering a scalable, benchtop-friendly alternative to mass spectrometry and immunoassays.

Market Cap
$166.0M
Founded
2013
Focus
Genetics & Genomics

QSI · Stock Price

USD 0.853.82 (-81.90%)

Historical price data

AI Company Overview

Founded in 2013 by Jonathan Rothberg, Quantum-Si is on a mission to power the post-genomic era by democratizing single-molecule protein analysis. Its flagship Platinum Pro instrument and associated kits provide a streamlined workflow for applications ranging from protein identification and variant detection to antibody characterization and ultrasensitive protein detection. As a public company, Quantum-Si is positioned to transform proteomics research and drug development by offering a scalable, benchtop-friendly alternative to mass spectrometry and immunoassays.

Technology Platform

A benchtop next-generation protein sequencing (NGPS) platform that uses single-molecule kinetic signatures to sequence peptides and detect proteins with single-amino-acid resolution, enabling real-time analysis of proteoforms and post-translational modifications.

Opportunities

The primary growth opportunity lies in displacing and complementing complex mass spectrometry workflows in proteomics research with a benchtop, easy-to-use platform.
Long-term, the Ultrasensitive Protein Detection (USPD) application opens a path to the high-value clinical diagnostics market for neurological and inflammatory biomarkers through strategic partnerships.

Risk Factors

Key risks include slow market adoption of a novel technology against entrenched methods, competition from large incumbents and emerging startups, financial sustainability as a pre-profitability public company, and the need to continuously validate the platform's utility across diverse research applications.

Competitive Landscape

Main competitors are mass spectrometry giants (Thermo Fisher, Bruker) and high-sensitivity protein detection firms (Olink, Quanterix). Quantum-Si differentiates through single-molecule, single-amino-acid sequencing capability, real-time kinetic data, a benchtop form factor, and a workflow designed for accessibility without specialized expertise.

Company Info

TypePlatform
Founded2013
LocationUnited States
StagePre-clinical
RevenueEarly Revenue

Trading

TickerQSI
ExchangeNASDAQ

Partners

Stanford UniversityU.S. Naval Research Laboratory
SIMILAR COMPANIES
BASi Research Products
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
EydisBio
Pre-clinical · Cambridge
3Spine
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile